|
Richard Johnson, PhD, outlines the trends and challenges within the inhaled drug delivery market. Specifically, DPI delivery will be explored, including how the challenges with dry powder formulation can be overcome and what the future holds for DPIs.
|
|
|
Dr. Sam Lee, Cocrystal Pharma’s President and co-CEO, discusses the company’s latest achievements in antiviral drug development.
|
|
|
Shaukat Ali, PhD, and Jim Huang, PhD, provide a better understanding about some of the advantages of prefilled syringes, methods for manufacturing, and the syringe types commercially available.
|
|
|
John Merhige and William (“Bill”) Jaworski present how their two companies have worked closely together, using creative manufacturing strategies to produce a wide array of problem-solving drug delivery systems.
|
|
|
|
|

Oakwood Chemical is a leader in selling high quality reagents to academic, chemical, and pharmaceutical customers for over thirty years. Located in the South Carolina Lowcountry, we have over 10,000 square feet of laboratory space, as well as two large warehouses totaling 200,000 square feet with over 150,000 chemicals in stock. We offer benchtop to production quantities of inorganic and organic reagents, solvents, salts, catalysts, and biochemicals in numerous grades (reagent, anhydrous, ACS, HPLC, LCMS, NMR, USP) and in different amounts (from lab bench to industrial drum sizes). Let us help you in succeeding in this high growth industry. Click here for more.
|
 |
|
By: Mark Rauckhorst, Director Supply Chain and Project Management, Vetter Development Service USA. Inc.
Clinical trials are high-visibility milestones for investors, as this is often the first major step toward financial return on what has likely been years of investment …
|
|
 |
|
Pharmaceutical companies have traditionally been risk-averse, often adopting safe and well-established processes due to the conservative stance of regulatory agencies on novel methodologies. However, with the increasing complexity of drug molecules and the demand for newer and harsher reaction conditions, …
|
|
 |
|
Traditionally, lipid-based drug delivery, including SEDDS, for per-oral dosing have primarily been formulated as soft-gels or liquid-filled hard-gels. With ABISORB-DC, the bioavailability enhancing features of lipid-based drug delivery can be combined with the high-throughput and ease of manufacturing of direct …
|
|
|
|